BRIEF—Yukon 10th Canadian jurisdiction to announce biosimilars switching policy

The Canadian territory of Yukon has become the 10th jurisdiction in Canada to announce a biosimilars switching policy.

Starting April 3, residents of the remote territory who are enrolled in the Pharmacare and the Chronic Disease and Disability Program will have six months to work with their healthcare providers to make the transition from certain biologic drugs to a biosimilar, in order to maintain coverage.

The policy will initially apply to the inflammatory diseases drug Humira (adalimumab) and the diabetes product Lantus (insulin glargine), and will then be expanded to include additional biologics.

Earlier this week, the government of Newfoundland and Labrador had announced a biosimilars switching policy. Only three jurisdictions in the North American country are yet to do so.